Abstract
It was originally hoped that the presence of mutations in KRAS and other related genes would provide an easy answer as to whether to administer anti-EGFR antibody therapy to a given metastatic colorectal cancer patient. However, in nature nothing is simple, and there are a number of issues that practicing clinicians should be made aware of.
| Original language | English (US) |
|---|---|
| Journal | ONCOLOGY (United States) |
| Volume | 28 |
| Issue number | 2 |
| State | Published - Feb 15 2014 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research
